Switch theme
Sign up to access all valuation multiples
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
2015
42
Last FY Revenue n/a
Last FY EBITDA -$44.5M
-$12.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Q32 Bio achieved revenue of n/a and an EBITDA of -$44.5M.
Q32 Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Q32 Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$44.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$60.2M | XXX | -$66.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$48.4M | XXX | -$47.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Q32 Bio's stock price is $2.
Q32 Bio has current market cap of $24.0M, and EV of -$12.1M.
See Q32 Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$12.1M | $24.0M | XXX | XXX | XXX | XXX | $-4.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Q32 Bio has market cap of $24.0M and EV of -$12.1M.
Q32 Bio's trades at 1.8x EV/Revenue multiple, and 0.3x EV/EBITDA.
Equity research analysts estimate Q32 Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Q32 Bio has a P/E ratio of -0.5x.
See valuation multiples for Q32 Bio and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24.0M | XXX | $24.0M | XXX | XXX | XXX |
| EV (current) | -$12.1M | XXX | -$12.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQ32 Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.6M for the same period.
Q32 Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Q32 Bio's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Q32 Bio and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Q32 Bio acquired XXX companies to date.
Last acquisition by Q32 Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Q32 Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Q32 Bio founded? | Q32 Bio was founded in 2015. |
| Where is Q32 Bio headquartered? | Q32 Bio is headquartered in United States of America. |
| How many employees does Q32 Bio have? | As of today, Q32 Bio has 42 employees. |
| Who is the CEO of Q32 Bio? | Q32 Bio's CEO is Ms. Jodie P. Morrison. |
| Is Q32 Bio publicy listed? | Yes, Q32 Bio is a public company listed on NAS. |
| What is the stock symbol of Q32 Bio? | Q32 Bio trades under QTTB ticker. |
| When did Q32 Bio go public? | Q32 Bio went public in 2024. |
| Who are competitors of Q32 Bio? | Similar companies to Q32 Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Q32 Bio? | Q32 Bio's current market cap is $24.0M |
| Is Q32 Bio profitable? | Yes, Q32 Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
